Companies / Nigeria
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Emzor Launches First ACT
October 2006 | Company Finance AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Nigerian drugmaker Emzor Pharmaceuticals - which has recently celebrated its 20th year - has launched a new malaria drug. Diasunate is an artemisinin-based combination therapy (ACT). The WHO recommends that using ACTs for anti-malaria programmes as a monotherapy can cause resistance in the malaria parasite. Diasunate is the only locally produced ACT in Nigeria.